Patricia Martin, the group’s president and CEO since 2019, last month announced she would step down to examine opportunities in the private sector and urged industry leaders to take a fresh look at the organization.
Read More
The pharmaceutical testing company said it plans to close two isolator facilities in Indianapolis and consolidate them with existing facilities in the United States.
Read More
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.
The nearly $24.3 million project, being led by Bloomington-based Applied Research Institute, or ARI, will serve as a biomanufacturing workforce training and innovation center when complete.
The company has a goal to build a massive bank of bone marrow from deceased organ donors to treat patients with blood cancers and improve organ transplantations.
Seeking to position Indiana as a global leader in agritechnology and life sciences, Gov. Mike Braun unveiled a lofty goal in a public announcement Tuesday morning.
IU Inc. was approved unanimously by the university’s board of trustees during its monthly meeting Friday in Indianapolis.
The $50 billion company is considering dividing its seed and pesticide businesses into separate companies, the Wall Street Journal reported
Syndeio Biosciences sees burgeoning potential to treat mental health and cognitive conditions, including Alzheimer’s and depression, with therapies that target the almost countless minuscule brain synapses that give people the ability to think and function.
Indianapolis-based Gate Neurosciences, which is in clinical trials of a medicine to treat depression, plans to acquire California-based biotech startup Boost Neuroscience.
Known as IU LAB and supported by a $138 million grant from the Lilly Endowment, the IU Launch Accelerator for Biosciences will be based at the 16 Tech Innovation District.
The gift is the largest grant that Indiana University has ever received in support of research and development. IU President Pamela Whitten said the funding will help “change the very landscape of our capital city and state.”
Corteva, the Indianapolis-based seed and crop protection giant, formed a joint venture with the startup, Pairwise, based in Durham, North Carolina, aimed at increasing crop yield for food, fuel and fiber production.
The five-year-old, clinical-stage drugmaker has already raised more than $213 million to develop therapeutics to treat rare endocrine disorders, a huge amount for a startup.
MBX is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity.
Stevanato, an Italian-based life sciences company that makes glass vials and syringes for pharmaceuticals, has committed to paying employees at its new Fishers facility no less than $70,000 annually.
Indiana’s Heartland BioWorks Hub was one of 12 hubs chosen to split $500 million in implementation funding stemming from the CHIPS and Science Act.
Roche has come under pressure to improve its pipeline with medicines it can commercialize soon as a windfall of revenue from products used in the COVID-19 pandemic comes to an end.
Following a $45 million renovation, RayzeBio plans to use the plant to make Actinium 225, a radioisotope used for targeted therapy for cancer.
Kyle Mohler founded Insignum Agtech with the idea of rearranging bits of corn’s DNA, then inserting them into popular field-corn hybrids.
Elon Musk’s Neuralink is one of many groups working on linking brains to computers, efforts aimed at helping treat brain disorders, overcoming brain injuries and other applications.
The acquisition is designed to accelerate Indianapolis-based Corteva’s biologicals business and make it one of the largest players in the market.
